Obesity diminishes response to PD-1-based immunotherapies in renal cancer

Background Obesity is a major risk factor for renal cancer, yet our understanding of its effects on antitumor immunity and immunotherapy outcomes remains incomplete. Deciphering these associations is critical, given the growing clinical use of immune checkpoint inhibitors for metastatic disease and...

Deskribapen osoa

Gorde:

Xehetasun bibliografikoak
Egile Nagusiak:	Peng Li, Amani Makkouk, Jennifer Gordetsky, Eddy Yang, Lewis Thomas, Yousef Zakharia, George J Weiner, Aliasger K Salem, Lakshminarayanan Nandagopal, Hesham Yasin, Rohan Garje, Shannon K Boi, Rachael M Orlandella, Justin Tyler Gibson, William James Turbitt, Gal Wald, Claire Buchta Rosean, Katlyn E Norris, Megan Bing, Laura Bertrand, Brett P Gross, Dmytro Starenki, Kristine I Farag, Robert E Sorge, James A Brown, David M Lubaroff, Rebecca C Arend, Kenneth Nepple, Tatiana T Marquez-Lago, Lyse A Norian
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	BMJ Publishing Group 2020-10-01
Saila:	Journal for ImmunoTherapy of Cancer
Sarrera elektronikoa:	https://jitc.bmj.com/content/8/2/e000725.full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Obesity diminishes response to PD-1-based immunotherapies in renal cancer

Antzeko izenburuak